{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T10:02:45Z","timestamp":1785578565864,"version":"3.56.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T00:00:00Z","timestamp":1627430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T00:00:00Z","timestamp":1627430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"GlaxoSmithKline and Agencia Nacional de Promocion Cientifica y Tecnologica","award":["PAE 2014-0010\/03"],"award-info":[{"award-number":["PAE 2014-0010\/03"]}]},{"DOI":"10.13039\/501100003074","name":"Agencia Nacional de Promoci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","doi-asserted-by":"publisher","award":["PICT 2016-4570"],"award-info":[{"award-number":["PICT 2016-4570"]}],"id":[{"id":"10.13039\/501100003074","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Brucella lumazine synthase (BLS) is a homodecameric protein that activates dendritic cells via toll like receptor 4, inducing the secretion of pro-inflammatory cytokines and chemokines. We have previously shown that BLS has a therapeutic effect in B16 melanoma-bearing mice only when administered at early stages of tumor growth. In this work, we study the mechanisms underlying the therapeutic effect of BLS, by analyzing the tumor microenvironment. Administration of BLS at early stages of tumor growth induces high levels of serum IFN-\u03b3, as well as an increment of hematopoietic immune cells within the tumor. Moreover, BLS-treatment increases the ratio of effector to regulatory cells. However, all treated mice eventually succumb to the tumors. Therefore, we combined BLS administration with anti-PD-1 treatment. Combined treatment increases the outcome of both monotherapies. In conclusion, we show that the absence of the therapeutic effect at late stages of tumor growth correlates with low levels of serum IFN-\u03b3 and lower infiltration of immune cells in the tumor, both of which are essential to delay tumor growth. Furthermore, the combined treatment of BLS and PD-1 blockade shows that BLS could be exploited as an essential immunomodulator in combination therapy with an immune checkpoint blockade to treat skin cancer.<\/jats:p>","DOI":"10.1038\/s41598-021-94837-7","type":"journal-article","created":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T10:02:43Z","timestamp":1627466563000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["A TLR4 agonist improves immune checkpoint blockade treatment by increasing the ratio of effector to regulatory cells within the tumor microenvironment"],"prefix":"10.1038","volume":"11","author":[{"given":"A.","family":"Farias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Puttur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. J.","family":"Goldin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. A.","family":"Goldbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. M.","family":"Berguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,28]]},"reference":[{"key":"94837_CR1","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2016.06.32","author":"P Diamantopoulos","year":"2016","unstructured":"Diamantopoulos, P. & Gogas, H. Melanoma immunotherapy dominates the field. Ann. Transl. Med. https:\/\/doi.org\/10.21037\/atm.2016.06.32 (2016).","journal-title":"Ann. Transl. Med."},{"key":"94837_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2015.12.002","author":"Z Zhu","year":"2016","unstructured":"Zhu, Z., Liu, W. & Gotlieb, V. The rapidly evolving therapies for advanced melanoma-towards immunotherapy, molecular targeted therapy, and beyond. Crit. Rev. Oncol. Hematol. https:\/\/doi.org\/10.1016\/j.critrevonc.2015.12.002 (2016).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"94837_CR3","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei, S. C., Duffy, C. R. & Allison, J. P. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 8, 1069\u20131086 (2018).","journal-title":"Cancer Discov."},{"key":"94837_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30366-7","author":"FS Hodi","year":"2016","unstructured":"Hodi, F. S. et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. https:\/\/doi.org\/10.1016\/S1470-2045(16)30366-7 (2016).","journal-title":"Lancet Oncol."},{"key":"94837_CR5","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad7118","author":"W Zou","year":"2016","unstructured":"Zou, W., Wolchok, J. D. & Chen, L. PD-L1 (B7\u2013H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.aad7118 (2016).","journal-title":"Sci. Transl. Med."},{"key":"94837_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.03.045","author":"SL Topalian","year":"2015","unstructured":"Topalian, S. L. et al. Immunotherapy: The path to win the war on cancer?. Cell https:\/\/doi.org\/10.1016\/j.cell.2015.03.045 (2015).","journal-title":"Cell"},{"key":"94837_CR7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030","author":"J Larkin","year":"2015","unstructured":"Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa1504030 (2015).","journal-title":"N. Engl. J. Med."},{"key":"94837_CR8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.critrevonc.2017.03.003","volume":"113","author":"A Sindoni","year":"2017","unstructured":"Sindoni, A., Minutoli, F., Ascenti, G. & Pergolizzi, S. Combination of immune checkpoint inhibitors and radiotherapy: Review of the literature. Crit. Rev. Oncol. Hematol. 113, 63\u201370 (2017).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"94837_CR9","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s11523-018-0589-7","volume":"13","author":"MJ Braunstein","year":"2018","unstructured":"Braunstein, M. J., Kucharczyk, J. & Adams, S. Targeting toll-like receptors for cancer therapy. Target. Oncol. 13, 583\u2013598 (2018).","journal-title":"Target. Oncol."},{"key":"94837_CR10","doi-asserted-by":"publisher","first-page":"4663","DOI":"10.18632\/oncotarget.3081","volume":"6","author":"S Sch\u00f6lch","year":"2015","unstructured":"Sch\u00f6lch, S. et al. Radiotherapy combined with TLR7\/8 activation induces strong immune responses against gastrointestinal tumors. Oncotarget 6, 4663\u20134676 (2015).","journal-title":"Oncotarget"},{"key":"94837_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-010-0833-1","author":"G Schreibelt","year":"2010","unstructured":"Schreibelt, G. et al. Toll-like receptor expression and function in human dendritic cell subsets: Implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol. Immunother. https:\/\/doi.org\/10.1007\/s00262-010-0833-1 (2010).","journal-title":"Cancer Immunol. Immunother."},{"key":"94837_CR12","doi-asserted-by":"publisher","DOI":"10.2217\/imt.09.70","author":"S Adams","year":"2009","unstructured":"Adams, S. Toll-like receptor agonists in cancer therapy. Immunotherapy https:\/\/doi.org\/10.2217\/imt.09.70 (2009).","journal-title":"Immunotherapy"},{"key":"94837_CR13","doi-asserted-by":"publisher","DOI":"10.4161\/onci.20931","author":"E Vacchelli","year":"2012","unstructured":"Vacchelli, E. et al. Trial watch: FDA-approved toll-like receptor agonists for cancer therapy. Oncoimmunology https:\/\/doi.org\/10.4161\/onci.20931 (2012).","journal-title":"Oncoimmunology"},{"key":"94837_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00878","author":"X Cen","year":"2018","unstructured":"Cen, X., Liu, S. & Cheng, K. The role of toll-like receptor in inflammation and tumor immunity. Front. Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2018.00878 (2018).","journal-title":"Front. Pharmacol."},{"key":"94837_CR15","doi-asserted-by":"publisher","DOI":"10.1006\/jmbi.2000.3640","author":"BC Braden","year":"2000","unstructured":"Braden, B. C., Velikovsky, C. A., Cauerhff, A. A., Polikarpov, I. & Goldbaum, F. A. Divergence in macromolecular assembly: X-ray crystallographic structure analysis of lumazine synthase from Brucella abortus. J. Mol. Biol. https:\/\/doi.org\/10.1006\/jmbi.2000.3640 (2000).","journal-title":"J. Mol. Biol."},{"key":"94837_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/prot.20248","author":"DA Laplagne","year":"2004","unstructured":"Laplagne, D. A. et al. Engineering of a polymeric bacterial protein as a scaffold for the multiple display of peptides. Proteins Struct. Funct. Genet. https:\/\/doi.org\/10.1002\/prot.20248 (2004).","journal-title":"Proteins Struct. Funct. Genet."},{"key":"94837_CR17","doi-asserted-by":"publisher","unstructured":"Berguer, P. M., Mundi\u00f1ano, J., Piazzon, I. & Goldbaum, F. A. A polymeric bacterial protein activates dendritic cells via TLR4. J. Immunol. 176(4):2366\u201372 https:\/\/doi.org\/10.4049\/jimmunol.176.4.2366 (2006).","DOI":"10.4049\/jimmunol.176.4.2366"},{"key":"94837_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0045705","author":"PM Berguer","year":"2012","unstructured":"Berguer, P. M. et al. A polymeric protein induces specific cytotoxicity in a TLR4 dependent manner in the absence of adjuvants. PLoS ONE https:\/\/doi.org\/10.1371\/journal.pone.0045705 (2012).","journal-title":"PLoS ONE"},{"key":"94837_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126827","author":"AH Rossi","year":"2015","unstructured":"Rossi, A. H. et al. Brucella spp. lumazine synthase induces a TLR4-mediated protective response against B16 melanoma in mice. PLoS ONE https:\/\/doi.org\/10.1371\/journal.pone.0126827 (2015).","journal-title":"PLoS ONE"},{"key":"94837_CR20","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1158\/0008-5472.CAN-11-1792","volume":"72","author":"AM Lesokhin","year":"2012","unstructured":"Lesokhin, A. M. et al. Monocytic CCR2+ myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res. 72, 876\u2013886 (2012).","journal-title":"Cancer Res."},{"key":"94837_CR21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0915174107","author":"MA Curran","year":"2010","unstructured":"Curran, M. A., Montalvo, W., Yagita, H. & Allison, J. P. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl. Acad. Sci. https:\/\/doi.org\/10.1073\/pnas.0915174107 (2010).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"94837_CR22","doi-asserted-by":"publisher","first-page":"8509","DOI":"10.1002\/jcp.27782","volume":"234","author":"B Farhood","year":"2019","unstructured":"Farhood, B., Najafi, M. & Mortezaee, K. CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review. J. Cell. Physiol. 234, 8509\u20138521 (2019).","journal-title":"J. Cell. Physiol."},{"key":"94837_CR23","doi-asserted-by":"publisher","DOI":"10.1097\/01.cji.0000436722.46675.4a","author":"MG Lechner","year":"2013","unstructured":"Lechner, M. G. et al. Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy. J. Immunother. https:\/\/doi.org\/10.1097\/01.cji.0000436722.46675.4a (2013).","journal-title":"J. Immunother."},{"key":"94837_CR24","doi-asserted-by":"publisher","unstructured":"Vilgelm, A. E. & Richmond, A. Chemokins modulate immune surveillance in tumorignesis, metastatsis, and response to immunotherapy. Front. Immunol.\u00a010, 333. https:\/\/doi.org\/10.3389\/fimmu.2019.00333 (2019).","DOI":"10.3389\/fimmu.2019.00333"},{"key":"94837_CR25","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","volume":"16","author":"Y Togashi","year":"2019","unstructured":"Togashi, Y., Shitara, K. & Nishikawa, H. Regulatory T cells in cancer immunosuppression\u2014Implications for anticancer therapy. Nat. Rev. Clin. Oncol. 16, 356\u2013371 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"94837_CR26","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.3389\/fimmu.2018.01909","volume":"9","author":"A De Sousa Linhares","year":"2018","unstructured":"De Sousa Linhares, A., Leitner, J., Grabmeier-Pfistershammer, K. & Steinberger, P. Not all immune checkpoints are created equal. Front. Immunol. 9, 1909 (2018).","journal-title":"Front. Immunol."},{"key":"94837_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00083","author":"H Lu","year":"2014","unstructured":"Lu, H. TLR agonists for cancer immunotherapy: Tipping the balance between the immune stimulatory and inhibitory effects. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2014.00083 (2014).","journal-title":"Front. Immunol."},{"key":"94837_CR28","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1158\/2326-6066.CIR-18-0277","volume":"6","author":"JA Trujillo","year":"2018","unstructured":"Trujillo, J. A., Sweis, R. F., Bao, R. & Luke, J. J. T cell\u2013inflamed versus Non-T cell-inflamed tumors: A conceptual framework for cancer immunotherapy drug development and combination therapy selection. Cancer Immunol. Res. 6, 990\u20131000 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"94837_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.09.035","author":"MF Sanmamed","year":"2018","unstructured":"Sanmamed, M. F. & Chen, L. A paradigm shift in cancer immunotherapy: From enhancement to normalization. Cell https:\/\/doi.org\/10.1016\/j.cell.2018.09.035 (2018).","journal-title":"Cell"},{"key":"94837_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.03.030","author":"P Sharma","year":"2015","unstructured":"Sharma, P. & Allison, J. P. Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential. Cell https:\/\/doi.org\/10.1016\/j.cell.2015.03.030 (2015).","journal-title":"Cell"},{"key":"94837_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.gde.2013.11.008","author":"S Budhu","year":"2014","unstructured":"Budhu, S., Wolchok, J. & Merghoub, T. The importance of animal models in tumor immunity and immunotherapy. Curr. Opin. Genet. Dev. https:\/\/doi.org\/10.1016\/j.gde.2013.11.008 (2014).","journal-title":"Curr. Opin. Genet. Dev."},{"key":"94837_CR32","doi-asserted-by":"publisher","unstructured":"Salaun, B., Coste, I., Rissoan, M.-C., Lebecque, S. J. & Renno, T. TLR3 can directly trigger apoptosis in human cancer cells. J. Immunol. 176(8):4894\u2013901 https:\/\/doi.org\/10.4049\/jimmunol.176.8.4894 (2006).","DOI":"10.4049\/jimmunol.176.8.4894"},{"key":"94837_CR33","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-0079","author":"V Andreani","year":"2007","unstructured":"Andreani, V., Gatti, G., Simonella, L., Rivero, V. & Maccioni, M. Activation of toll-like receptor 4 on tumor cells in vitro inhibits subsequent tumor growth in vivo. Cancer Res. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-0079 (2007).","journal-title":"Cancer Res."},{"key":"94837_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2016.01.004","author":"V Kumar","year":"2016","unstructured":"Kumar, V., Patel, S., Tcyganov, E. & Gabrilovich, D. I. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. https:\/\/doi.org\/10.1016\/j.it.2016.01.004 (2016).","journal-title":"Trends Immunol."},{"key":"94837_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/bs.ai.2020.06.002","author":"T Bald","year":"2020","unstructured":"Bald, T., Pedde, A. M., Corvino, D. & B\u00f6ttcher, J. P. The role of NK cell as central communicators in cancer immunity. Adv. Immunol. https:\/\/doi.org\/10.1016\/bs.ai.2020.06.002 (2020).","journal-title":"Adv. Immunol."},{"key":"94837_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2017.12.007","author":"A Glasner","year":"2018","unstructured":"Glasner, A. et al. NKp46 receptor-mediated interferon-\u03b3 production by natural killer cells increases fibronectin 1 to alter tumor architecture and control metastasis. Immunity https:\/\/doi.org\/10.1016\/j.immuni.2017.12.007 (2018).","journal-title":"Immunity"},{"key":"94837_CR37","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.5.2860","author":"WS Webster","year":"2007","unstructured":"Webster, W. S. et al. Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine. J. Immunol. https:\/\/doi.org\/10.4049\/jimmunol.179.5.2860 (2007).","journal-title":"J. Immunol."},{"key":"94837_CR38","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0900974","author":"V Pulko","year":"2009","unstructured":"Pulko, V. et al. TLR3-stimulated dendritic cells up-regulate B7-H1 expression and influence the magnitude of CD8 T cell responses to tumor vaccination. J. Immunol. https:\/\/doi.org\/10.4049\/jimmunol.0900974 (2009).","journal-title":"J. Immunol."},{"key":"94837_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-015-0093-y","author":"H Noh","year":"2015","unstructured":"Noh, H. et al. Immune checkpoint regulator PD-L1 expression on tumor cells by contacting CD11b positive bone marrow derived stromal cells. Cell Commun. Signal. https:\/\/doi.org\/10.1186\/s12964-015-0093-y (2015).","journal-title":"Cell Commun. Signal."},{"key":"94837_CR40","doi-asserted-by":"publisher","first-page":"eaav7816","DOI":"10.1126\/scitranslmed.aav7816","volume":"11","author":"RM Zemek","year":"2019","unstructured":"Zemek, R. M. et al. Sensitization to immune checkpoint blockade through activation of a STAT1\/NK axis in the tumor microenvironment. Sci. Transl. Med. 11, eaav7816 (2019).","journal-title":"Sci. Transl. Med."},{"key":"94837_CR41","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1002\/pro.3151","volume":"26","author":"Y Hiriart","year":"2017","unstructured":"Hiriart, Y. et al. Characterization of structural and immunological properties of a fusion protein between flagellin from Salmonella and lumazine synthase from Brucella. Protein Sci. 26, 1049\u20131059 (2017).","journal-title":"Protein Sci."},{"key":"94837_CR42","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.micinf.2005.12.006","volume":"8","author":"G Rosas","year":"2006","unstructured":"Rosas, G. et al. Brucella spp. lumazine synthase: A novel adjuvant and antigen delivery system to effectively induce oral immunity. Microbes Infect. 8, 1277\u20131286 (2006).","journal-title":"Microbes Infect."},{"key":"94837_CR43","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1002\/prot.20635","volume":"61","author":"PO Craig","year":"2005","unstructured":"Craig, P. O. et al. Multiple display of a protein domain on a bacterial polymeric scaffold. Proteins Struct. Funct. Genet. 61, 1089\u20131100 (2005).","journal-title":"Proteins Struct. Funct. Genet."},{"key":"94837_CR44","doi-asserted-by":"publisher","first-page":"768","DOI":"10.4161\/onci.19727","volume":"1","author":"S Kreiter","year":"2012","unstructured":"Kreiter, S., Castle, J. C., T\u00fcreci, \u00d6. & Sahin, U. Targeting the tumor mutanome for personalized vaccination therapy. Oncoimmunology 1, 768\u2013769 (2012).","journal-title":"Oncoimmunology"},{"key":"94837_CR45","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1158\/0008-5472.CAN-11-3722","volume":"72","author":"JC Castle","year":"2012","unstructured":"Castle, J. C. et al. Exploiting the mutanome for tumor vaccination. Cancer Res. 72, 1081\u20131091 (2012).","journal-title":"Cancer Res."},{"key":"94837_CR46","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nature13988","volume":"515","author":"MM Gubin","year":"2014","unstructured":"Gubin, M. M. et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515, 577\u2013581 (2014).","journal-title":"Nature"},{"key":"94837_CR47","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1172\/JCI80009","volume":"125","author":"CJM Melief","year":"2015","unstructured":"Melief, C. J. M., Van Hall, T., Arens, R., Ossendorp, F. & Van Der Burg, S. H. Therapeutic cancer vaccines. J. Clin. Investig. 125, 3401\u20133412 (2015).","journal-title":"J. Clin. Investig."},{"key":"94837_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-1759(98)00204-X","author":"MB Lutz","year":"1999","unstructured":"Lutz, M. B. et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immunol. Methods https:\/\/doi.org\/10.1016\/S0022-1759(98)00204-X (1999).","journal-title":"J. Immunol. Methods"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94837-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94837-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94837-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T11:55:33Z","timestamp":1670068533000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94837-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,28]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["94837"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-94837-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,28]]},"assertion":[{"value":"4 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15406"}}